Determinants on Rocuronium Dose for Deep Block in Bariatric Surgery
Analysis of Determinants on the Dose of Rocuronium for Deep Neuromuscular Blockade in Bariatric Surgery.
1 other identifier
observational
90
0 countries
N/A
Brief Summary
Find out the deciding factor(total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index, skeletal muscle mass, body fat) of neuromuscular blocker dose for deep neuromuscular blockade in bariatric surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2021
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2021
CompletedFirst Submitted
Initial submission to the registry
January 12, 2021
CompletedFirst Posted
Study publicly available on registry
January 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2021
CompletedJanuary 14, 2021
January 1, 2021
9 months
January 12, 2021
January 12, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the highest correlation coefficient
the relationship of rocuronium for deep neuromuscular blockade in bariatric surgery and 8 factors (corrected body weight, ideal body weight, lean body weight, fat-free mass, body mass index, skeletal muscle mass, body fat)
preoperative 1 days to postoperative 1 days
Secondary Outcomes (3)
onset time of rocuronium
preoperative 1 days to postoperative 1 days
time to deep neuromuscular blockade
preoperative 1 days to postoperative 1 days
Recovery time
preoperative 1 days to postoperative 1 days
Study Arms (1)
obese patients
obese patients underwent bariatric surgery
Interventions
obese patients who underwent bariatric surgery
Eligibility Criteria
obese patients who scheduled bariatric surgery
You may qualify if:
- Patients aged 20-80 and American Society of Anesthesiology Physical Grade (ASA) I-II, who undergo bariatric surgery
You may not qualify if:
- kidney disease (GFR\<60)
- allergy to study drugs
- decline participation
- side effect of propofol and remifentanil
- when anesthesia does not maintain the level of alertness (BIS) below 60 even when the anesthetic dose is increased, or when hemodynamic instability such as bradycardia and hypotension appears
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Choi YJ, Hee Kim Y, Bae GE, Yu JH, Yoon SZ, Kang HW, Lee KS, Kim JH, Lee YS. Relationship between the muscle relaxation effect and body muscle mass measured using bioelectrical impedance analysis: A nonrandomized controlled trial. J Int Med Res. 2019 Apr;47(4):1521-1532. doi: 10.1177/0300060518822197. Epub 2019 Feb 5.
PMID: 30719949BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 12, 2021
First Posted
January 14, 2021
Study Start
January 1, 2021
Primary Completion
October 1, 2021
Study Completion
October 1, 2021
Last Updated
January 14, 2021
Record last verified: 2021-01